These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 23430560)

  • 1. CRIM-Negative Pompe Disease Patients with Satisfactory Clinical Outcomes on Enzyme Replacement Therapy.
    Khallaf HHA; Propst J; Geffrard S; Botha E; Pervaiz MA
    JIMD Rep; 2013; 9():133-137. PubMed ID: 23430560
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Characterization of immune response in Cross-Reactive Immunological Material (CRIM)-positive infantile Pompe disease patients treated with enzyme replacement therapy.
    Desai AK; Kazi ZB; Bali DS; Kishnani PS
    Mol Genet Metab Rep; 2019 Sep; 20():100475. PubMed ID: 31193175
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Successful immune tolerance induction to enzyme replacement therapy in CRIM-negative infantile Pompe disease.
    Messinger YH; Mendelsohn NJ; Rhead W; Dimmock D; Hershkovitz E; Champion M; Jones SA; Olson R; White A; Wells C; Bali D; Case LE; Young SP; Rosenberg AS; Kishnani PS
    Genet Med; 2012 Jan; 14(1):135-42. PubMed ID: 22237443
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cross-reactive immunologic material status affects treatment outcomes in Pompe disease infants.
    Kishnani PS; Goldenberg PC; DeArmey SL; Heller J; Benjamin D; Young S; Bali D; Smith SA; Li JS; Mandel H; Koeberl D; Rosenberg A; Chen YT
    Mol Genet Metab; 2010 Jan; 99(1):26-33. PubMed ID: 19775921
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A favorable outcome in an infantile-onset Pompe patient with cross reactive immunological material (CRIM) negative disease with high dose enzyme replacement therapy and adjusted immunomodulation.
    Curelaru S; Desai AK; Fink D; Zehavi Y; Kishnani PS; Spiegel R
    Mol Genet Metab Rep; 2022 Sep; 32():100893. PubMed ID: 35813979
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A new assay for fast, reliable CRIM status determination in infantile-onset Pompe disease.
    Wang Z; Okamoto P; Keutzer J
    Mol Genet Metab; 2014 Feb; 111(2):92-100. PubMed ID: 24044919
    [TBL] [Abstract][Full Text] [Related]  

  • 7. CRIM-negative infantile Pompe disease: 42-month treatment outcome.
    Rohrbach M; Klein A; Köhli-Wiesner A; Veraguth D; Scheer I; Balmer C; Lauener R; Baumgartner MR
    J Inherit Metab Dis; 2010 Dec; 33(6):751-7. PubMed ID: 20882352
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Teaching tolerance: New approaches to enzyme replacement therapy for Pompe disease.
    Cousens LP; Mingozzi F; van der Marel S; Su Y; Garman R; Ferreira V; Martin W; Scott DW; De Groot AS
    Hum Vaccin Immunother; 2012 Oct; 8(10):1459-64. PubMed ID: 23095864
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Predicting cross-reactive immunological material (CRIM) status in Pompe disease using GAA mutations: lessons learned from 10 years of clinical laboratory testing experience.
    Bali DS; Goldstein JL; Banugaria S; Dai J; Mackey J; Rehder C; Kishnani PS
    Am J Med Genet C Semin Med Genet; 2012 Feb; 160C(1):40-9. PubMed ID: 22252923
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Long term clinical history of an Italian cohort of infantile onset Pompe disease treated with enzyme replacement therapy.
    Parini R; De Lorenzo P; Dardis A; Burlina A; Cassio A; Cavarzere P; Concolino D; Della Casa R; Deodato F; Donati MA; Fiumara A; Gasperini S; Menni F; Pagliardini V; Sacchini M; Spada M; Taurisano R; Valsecchi MG; Di Rocco M; Bembi B
    Orphanet J Rare Dis; 2018 Feb; 13(1):32. PubMed ID: 29422078
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Atypical immunologic response in a patient with CRIM-negative Pompe disease.
    Abbott MA; Prater SN; Banugaria SG; Richards SM; Young SP; Rosenberg AS; Kishnani PS
    Mol Genet Metab; 2011 Dec; 104(4):583-6. PubMed ID: 21889385
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A pilot study on using rapamycin-carrying synthetic vaccine particles (SVP) in conjunction with enzyme replacement therapy to induce immune tolerance in Pompe disease.
    Lim HH; Yi H; Kishimoto TK; Gao F; Sun B; Kishnani PS
    Mol Genet Metab Rep; 2017 Dec; 13():18-22. PubMed ID: 28761815
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Immune Tolerance-Adjusted Personalized Immunogenicity Prediction for Pompe Disease.
    De Groot AS; Desai AK; Lelias S; Miah SMS; Terry FE; Khan S; Li C; Yi JS; Ardito M; Martin WD; Kishnani PS
    Front Immunol; 2021; 12():636731. PubMed ID: 34220802
    [TBL] [Abstract][Full Text] [Related]  

  • 14. First successful concomitant therapy of immune tolerance induction therapy and desensitization in a CRIM-negative infantile Pompe patient.
    Emecen Sanli M; Ertoy Karagol HI; Kilic A; Aktasoglu E; Inci A; Okur I; Ezgu F; Tumer L
    J Pediatr Endocrinol Metab; 2022 Feb; 35(2):273-277. PubMed ID: 34561975
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Benefits of Prophylactic Short-Course Immune Tolerance Induction in Patients With Infantile Pompe Disease: Demonstration of Long-Term Safety and Efficacy in an Expanded Cohort.
    Desai AK; Baloh CH; Sleasman JW; Rosenberg AS; Kishnani PS
    Front Immunol; 2020; 11():1727. PubMed ID: 32849613
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A Race Against Time-Changing the Natural History of CRIM Negative Infantile Pompe Disease.
    Gupta P; Shayota BJ; Desai AK; Kiblawi F; Myridakis D; Messina J; Tah P; Tambini-King L; Kishnani PS
    Front Immunol; 2020; 11():1929. PubMed ID: 33013846
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Enzyme therapy and immune response in relation to CRIM status: the Dutch experience in classic infantile Pompe disease.
    van Gelder CM; Hoogeveen-Westerveld M; Kroos MA; Plug I; van der Ploeg AT; Reuser AJ
    J Inherit Metab Dis; 2015 Mar; 38(2):305-14. PubMed ID: 24715333
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Immune responses and hypercoagulation in ERT for Pompe disease are mutation and rhGAA dose dependent.
    Nayak S; Doerfler PA; Porvasnik SL; Cloutier DD; Khanna R; Valenzano KJ; Herzog RW; Byrne BJ
    PLoS One; 2014; 9(6):e98336. PubMed ID: 24897114
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Sustained immune tolerance induction in enzyme replacement therapy-treated CRIM-negative patients with infantile Pompe disease.
    Kazi ZB; Desai AK; Berrier KL; Troxler RB; Wang RY; Abdul-Rahman OA; Tanpaiboon P; Mendelsohn NJ; Herskovitz E; Kronn D; Inbar-Feigenberg M; Ward-Melver C; Polan M; Gupta P; Rosenberg AS; Kishnani PS
    JCI Insight; 2017 Aug; 2(16):. PubMed ID: 28814660
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Divergent clinical outcomes of alpha-glucosidase enzyme replacement therapy in two siblings with infantile-onset Pompe disease treated in the symptomatic or pre-symptomatic state.
    Matsuoka T; Miwa Y; Tajika M; Sawada M; Fujimaki K; Soga T; Tomita H; Uemura S; Nishino I; Fukuda T; Sugie H; Kosuga M; Okuyama T; Umeda Y
    Mol Genet Metab Rep; 2016 Dec; 9():98-105. PubMed ID: 27896132
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.